Xceleron Ltd.

https://www.xceleron.com

Founded in 1997 in York, UK, Xceleron provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. Xceleron pioneered the use of human microtracer and AMS and has unmatched robust processes and knowledge of experimental design. There are currently 6 drugs on the market that have used Xceleron AMS data in filing, and another 3 in late stages of development. In 2008, the company opened its US facility in Maryland. *

	Start	2003-02-01 renamed
	Group	Xceleron (Group)
	Predecessor	CBAMS Ltd. (Centre for Biomedical Accelerator Mass Spetrometry)
	Industry	drug discovery services
	Industry 2	contract research (drugs)

	Region	Heslington, North Yorkshire
	Country	United Kingdom (GB)
	Street	Innovation Way, York Biocentre
	City	YO10 5NY Heslington, York
	Tel	+44-1904-561561
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]